AMEP-EHVA T02
Research type
Research Study
Full title
Expectation, Motivation and Experience of HIV patients regarding participation to a European randomized phase II therapeutic HIV vaccine trial (EHVA T02/ANRS VRI07) with interruption of ART (AMEP-EHVA T02)
IRAS ID
256870
Contact name
Marta Boffito
Contact email
Sponsor organisation
Inserm-ANRS
Clinicaltrials.gov Identifier
Grant from the VRI, UPEC ANRS VRI 2018-19; Grant from ANRS, ANRS 95052
Duration of Study in the UK
2 years, 11 months, 31 days
Research summary
Curing HIV would have a major impact on public health, not only for people living with HIV - who are on long-term antiretroviral treatment, and have to live with different associated treatment side effects and comorbidities - but also for society, since a cure would stop the virus’s chain of transmission, and would reduce the very high costs of care currently needed for people living with HIV.
The participant will have already agreed to participate in the EHVA T01/ANRS VRI05 clinical trial, which aims to evaluate - either separately or in combination - two therapeutic vaccines against HIV and a monoclonal antibody, in HIV-positive people currently taking antiretroviral treatment.
The main objective of our social sciences study is to document the participant's expectations regarding this clinical trial and their motivations for participating in it, and to watch how these aspects change over time. We will also try to evaluate the participant's experience with the trial and their satisfaction with it, especially during the period of antiretroviral treatment interruption. These different aspects will be studied according to the characteristics of each participant, which is why we will also ask the participant quite personal questions.
REC name
London - South East Research Ethics Committee
REC reference
19/LO/0152
Date of REC Opinion
29 Mar 2019
REC opinion
Favourable Opinion